Compass Therapeutics (CMPX) Set to Post Quarterly Earnings on Wednesday

Posted by Stanley Muller on Oct 28th, 2026

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) is projected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.12) per share and revenue of $0.23 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 9:30 AM ET.

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, analysts expect Compass Therapeutics to post ($0.47) EPS for the current fiscal year and ($0.49) EPS for the next fiscal year.

Compass Therapeutics Price Performance

Shares of NASDAQ CMPX opened at $0.75 on Wednesday. The stock has a market capitalization of $134.60 million, a price-to-earnings ratio of -1.87 and a beta of 1.02. Compass Therapeutics has a 12 month low of $0.73 and a 12 month high of $6.88. The firm’s 50 day simple moving average is $1.56 and its 200-day simple moving average is $3.30.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on CMPX shares. Citizens Jmp decreased their target price on shares of Compass Therapeutics to $4.00 and set a “market outperform” rating for the company in a research note on Wednesday, September 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Thursday, October 15th. Wall Street Zen lowered shares of Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Lifesci Capital cut shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 22nd. Finally, Citigroup reiterated a “market outperform” rating on shares of Compass Therapeutics in a research report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.25.

Check Out Our Latest Stock Analysis on Compass Therapeutics

About Compass Therapeutics

(Get Free Report)

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.